cident cases of primary lung cancer were identified using the Rochester Epidemiology Project database; the project has maintained a comprehensive medical records linkage system for more than 60 years based on hospital adaptation of the International Classification of Diseases and International Classification of Diseases, Ninth Revision, codes. 2,3 Patient character- 1984-1990 (n = 257) 1991-1997 (n = 301) 1998-2004 (n = 400)
2005-2011 (n = 393)
Age-and sex-adjusted incidence rate per 100 000 person-years (95% CI) Trends in lung cancer incidence rates were determined based on decennial census data adjusted for the age and sex distribution of the US population in 2000. Cases were grouped into 4 calendar-year intervals (each 7 years) when assessing secular trends to minimize the annual rate fluctuations. Assuming a Poisson distribution, 95% confidence intervals for incidence rates were calculated with generalized linear models using the Poisson error structure and a log-link function.
4,5
The proportion of cases meeting USPSTF screening criteria were identified. The criteria included asymptomatic adults aged 55 to 80 years, having a 30 pack-year smoking history, and currently smoking or having quit within the past 15 years.
1 The
Cochran-Armitage trend test was used for comparing proportions. Two-sided P < .05 was considered statistically significant. Analyses were performed using SAS version 9.3 (SAS Institute Inc).
Results | There were 1351 patients with incident primary lung cancer between 1984 and 2011. The mean (SD) age was 68.1 (11.3) years and 54.9% were male. The age-and sex-adjusted incidence rate decreased from 52.3 (95% CI, 45.8-58.7) per 100 000 person-years in 1984-1990 to 44.1 (95% CI, 39.7-48.5) per 100 000 person-years in 2005-2011 (P < .001; Table) . Trend analyses showed a decline in men but not women. The proportion of patients with lung cancer who smoked more than 30 pack-years declined, and the proportion of former smokers, especially those who quit smoking more than 15 years ago, increased. We observed a decline in the relative proportion of patients with lung cancer meeting the USPSTF criteria overall from 56.8% (95% CI, 50.8%-62.9%) in 1984-1990 to 43.3% (95% CI, 38.4%-48.2%) in 2005-2011 (P < .001; Figure) . The proportion of patients who would have been eligible under the criteria decreased in women from 52.3% (95% CI, 42.9%-61.8%) to 36.6% (95% CI, 29.8%-43.4%) (P = .005) and in men from 60.0% (95% CI, 52.2%-67.8%) to 49.7% (95% CI, 42.8%-56.7%) (P = .03).
Discussion | The proportion of patients with lung cancer in Olmsted County meeting the USPSTF screening criteria decreased significantly between 1984 and 2011, with only 37% of female and 50% of male patients eligible for screening during the most recent interval. Our findings may reflect a temporal change in smoking patterns in which the proportion of adults with a 30 pack-year smoking history and having quit within 15 years declined. The secular trends in lung cancer incidence rates in Olmsted County are comparable with US Surveillance, Epidemiology and End Results registry data, 6 but may not be generalizable to the entire US population. The decline in the proportion of patients meeting USPSTF high-risk criteria indicates that an increasing number of patients with lung cancer would not have been candidates for screening. More sensitive screening criteria may need to be identified while balancing the potential harm from computed tomography. 1984-1990 1991-1997 1998-2004 2005-2011 1984-1990 1991-1997 1998-2004 2005-2011 Stratified by sex ered study that provides assurance that the studied arterial closure devices were noninferior to manual compression with regard to efficacy and complications. Nonetheless, the decision to use a closure device should offer a significant benefit of either decreased cost or improved outcome rather than simply being noninferior. The only clear benefit demonstrated in this study was the 9-minute reduction in time required to achieve hemostasis, which may be misleading. Time to hemostasis, defined as sheath removal to no bleeding, 3 is not an accurate measure of comparison. For both devices, the added time involved for angiographic evaluation of the artery, preparing the device, and deploying it occurred prior to removing the sheath. The primary benefit of an arterial closure device over manual compression, in most practices, is a reduction in time to ambulation that can result in decreased recovery room time. In the ISAR-CLOSURE trial, time to ambulation was not an end point, but the benefit was built into the methods (eg, the pressure bandage and presumably bedrest duration was set at 2 hours after device closure and 6 hours after manual compression). However in recent years, this benefit has been questioned because the traditional 4-to 6-hour bedrest requirement after femoral artery puncture has been shown to be excessive, with no increased complication risk after only 1 hour of immobilization. 4, 5 Noninferior safety and efficacy does not justify the use of a $250 device to save 9 minutes of manual compression. 
